COVID-19: India's first nasal vaccine by Bharat Biotech gets drug panel's nod for 'restricted use'

The Central Drugs Standard Control Organisation has approved the vaccine for primary immunisation against COVID-19 in the above 18 age group for 'restricted use in an emergency situation'

FP Staff September 06, 2022 15:51:54 IST
COVID-19: India's first nasal vaccine by Bharat Biotech gets drug panel's nod for 'restricted use'

Representational image. PTI

New Delhi: A nasal vaccine against COVID-19, developed by Covaxin-maker Bharat Biotech has been approved for “restricted use” by India’s top drug controller, Union health minister Mansukh Mandaviya said on Tuesday.

The Central Drugs Standard Control Organisation has approved the vaccine for primary immunisation against COVID-19 in the above 18 age group for “restricted use in an emergency situation.”

The union health minister also said that India has harnessed its science, R&D, and human resources in the fight against COVID-19 under PM Narendra Modi’s leadership.

According to a News18 report, in August, Bharat Biotech International Limited (BBIL) said that its COVID-19 intranasal vaccine (BBV154) has proven to be safe, well-tolerated, and immunogenic in subjects in controlled phase-3 clinical trials.

The trials were conducted with the help of nearly 4,000 volunteers, the report added.

With inputs from agencies

Read all the Latest News, Trending NewsCricket News, Bollywood News,
India News and Entertainment News here. Follow us on Facebook, Twitter and Instagram.

Updated Date:

also read

US official says Chinese President Xi Jinping 'unwilling to accept Covid-19 vaccines' despite protests
World

US official says Chinese President Xi Jinping 'unwilling to accept Covid-19 vaccines' despite protests

She added that while the recent demonstrations in the country do not pose a threat to Communist Party rule, they may have an impact on his personal standing

Why approval for Bharat Biotech’s iNCOVACC, world’s first intranasal COVID vaccine, is a big deal
Explainers

Why approval for Bharat Biotech’s iNCOVACC, world’s first intranasal COVID vaccine, is a big deal

Bharat Biotech says iNCOVACC has several advantages including being non-invasive and needle-free. Trained healthcare workers are not required to administer it, and it can eliminate needle-associated risks such as injuries and infections

Bharat Biotech’s Intranasal COVID-19 vaccine gets CDSCO approval
Health

Bharat Biotech’s Intranasal COVID-19 vaccine gets CDSCO approval

iNCOVACC is the world’s first Intranasal vaccine for COVID to receive approval for the primary 2-dose schedule, and heterologous booster dose